These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33665099)

  • 1. A mixed herbal extract as an adjunctive therapy for attention deficit hyperactivity disorder: A randomized placebo-controlled trial.
    Bae S; Park S; Han DH
    Integr Med Res; 2021 Sep; 10(3):100714. PubMed ID: 33665099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GC-TOF-MS-Based Metabolomic Analysis and Evaluation of the Effects of HX106, a Nutraceutical, on ADHD-Like Symptoms in Prenatal Alcohol Exposed Mice.
    Ju IG; Lee MY; Jeon SH; Huh E; Kim JH; Lee JK; Lee CH; Oh MS
    Nutrients; 2020 Oct; 12(10):. PubMed ID: 33023237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
    Akhondzadeh S; Mohammadi MR; Khademi M
    BMC Psychiatry; 2004 Apr; 4():9. PubMed ID: 15070418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aerobic exercise and attention deficit hyperactivity disorder: brain research.
    Choi JW; Han DH; Kang KD; Jung HY; Renshaw PF
    Med Sci Sports Exerc; 2015 Jan; 47(1):33-9. PubMed ID: 24824770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
    Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.
    Mohammadpour N; Jazayeri S; Tehrani-Doost M; Djalali M; Hosseini M; Effatpanah M; Davari-Ashtiani R; Karami E
    Nutr Neurosci; 2018 Apr; 21(3):202-209. PubMed ID: 27924679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.
    Findling RL; Bukstein OG; Melmed RD; López FA; Sallee FR; Arnold LE; Pratt RD
    J Clin Psychiatry; 2008 Jan; 69(1):149-59. PubMed ID: 18312050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
    Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
    Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial.
    Rafeiy-Torghabeh M; Ashraf-Ganjouei A; Moradi K; Bagheri S; Mohammadi MR; Akhondzadeh S
    Eur Child Adolesc Psychiatry; 2021 May; 30(5):799-807. PubMed ID: 32449130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
    Reimherr FW; Williams ED; Strong RE; Mestas R; Soni P; Marchant BK
    J Clin Psychiatry; 2007 Jan; 68(1):93-101. PubMed ID: 17284136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
    Huss M; Ginsberg Y; Tvedten T; Arngrim T; Philipsen A; Carter K; Chen CW; Kumar V
    Adv Ther; 2014 Jan; 31(1):44-65. PubMed ID: 24371021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
    Schrantee A; Tamminga HG; Bouziane C; Bottelier MA; Bron EE; Mutsaerts HJ; Zwinderman AH; Groote IR; Rombouts SA; Lindauer RJ; Klein S; Niessen WJ; Opmeer BC; Boer F; Lucassen PJ; Andersen SL; Geurts HM; Reneman L
    JAMA Psychiatry; 2016 Sep; 73(9):955-62. PubMed ID: 27487479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.
    Konstenius M; Jayaram-Lindström N; Guterstam J; Beck O; Philips B; Franck J
    Addiction; 2014 Mar; 109(3):440-9. PubMed ID: 24118269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.
    Volkow ND; Wang GJ; Newcorn J; Telang F; Solanto MV; Fowler JS; Logan J; Ma Y; Schulz K; Pradhan K; Wong C; Swanson JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):932-40. PubMed ID: 17679638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
    Smith A; Cubillo A; Barrett N; Giampietro V; Simmons A; Brammer M; Rubia K
    Biol Psychiatry; 2013 Oct; 74(8):615-22. PubMed ID: 23731741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating nicotine dependence by targeting attention-deficit/ hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response.
    Nunes EV; Covey LS; Brigham G; Hu MC; Levin FR; Somoza EC; Winhusen TM
    J Clin Psychiatry; 2013 Oct; 74(10):983-90. PubMed ID: 24229749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Rösler M; Fischer R; Ammer R; Ose C; Retz W
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.